Humacyte, Inc. (HUMA) - Dilution Analysis

10-Q filing | 222.0M shares outstanding

8-K filing: Humacyte, Inc. entered into securities purchase agreements to issue and sell 25,000,000 shares of common stock at $0.80 per share in a registered direct offering. ($18.4M proceeds)

10-Q filing | 187.3M shares outstanding

S-3 filing: Humacyte, Inc. is offering and selling up to $350,000,000 in the aggregate of common stock, preferred stock, warrants, debt securities, subscription rights and units, either individually or in combination, from time to time.

10-Q filing | 155.1M shares outstanding

10-K filing | 155.1M shares outstanding

8-K filing: Humacyte, Inc. entered into an underwriting agreement for the issuance and sale of 25,000,000 shares of common stock at $2.00 per share, with an option for the underwriters to purchase an additional 3,750,000 shares. ($46.6M proceeds)

8-K filing: Humacyte, Inc. entered into a securities purchase agreement to issue and sell 2,808,988 shares of common stock and warrants to purchase up to 2,808,988 shares of common stock in a registered direct offering at a price of $5.34 per share and accompanying warrant, expected to close on November 15, 2024.

10-Q filing | 119.4M shares outstanding

8-K filing: Humacyte, Inc. entered into a securities purchase agreement to issue and sell 5,681,820 shares of common stock and warrants to purchase up to 5,681,820 shares of common stock in a registered direct offering at a price of $5.28 per share and accompanying warrant, with the offering expected to close on October 7, 2024.

8-K filing: Humacyte, Inc. entered into a purchase agreement with Lincoln Park Capital Fund, LLC, allowing the company to sell up to $50,000,000 of its common stock to Lincoln Park, subject to certain limitations and conditions.

10-Q filing | 119.2M shares outstanding

10-Q filing | 108.2M shares outstanding

10-K filing | 119.1M shares outstanding

8-K filing: Humacyte, Inc. entered into an underwriting agreement for the issuance and sale of 13,400,000 shares of its common stock at $3.00 per share, with an option for the underwriters to purchase an additional 2,010,000 shares. ($46.23M proceeds)

10-Q filing | 103.4M shares outstanding

10-Q filing | 103.4M shares outstanding

S-3 filing: The filing relates to the potential issuance of up to 1,333,334 shares of common stock upon exercise of an option, with the company potentially receiving up to $10,000,000 in proceeds.

10-Q filing | 103.3M shares outstanding

10-K filing | 103.1M shares outstanding

10-Q filing | 103.0M shares outstanding

POS AM filing: Post-Effective Amendment No. 3 is being filed to terminate the effectiveness of the Original Registration Statement and to deregister all the Registered Shares that remain unsold under the Original Registration Statement.

S-3 filing: The filing is an S-3 form for an at-the-market offering of common stock with an aggregate offering price of up to $80,000,000. The company intends to use the net proceeds from this offering to fund the continued development of the product candidates in their pipeline and for working capital and general corporate purposes.

S-3 filing: This S-3 filing includes the offering of up to 5,177,500 shares of common stock issuable upon the exercise of warrants and up to 89,716,840 shares of common stock by selling stockholders.

10-Q filing | 103.0M shares outstanding

10-Q filing | 103.0M shares outstanding

POS AM filing: This POS AM filing relates to the issuance of up to 5,177,500 shares of common stock upon exercise of warrants and the offer and sale of up to 89,706,840 shares of common stock by selling stockholders.

10-K filing | 103.0M shares outstanding

POS AM filing: This POS AM filing relates to the issuance of up to 5,177,500 shares of common stock upon exercise of warrants and the resale of up to 90,006,840 shares of common stock by selling stockholders.

10-Q filing | 103.0M shares outstanding

S-1/A filing: This S-1/A filing registers shares of common stock offered by the company and selling stockholders, including shares issuable upon the exercise of warrants and shares subject to lock-up agreements.

S-1 filing: This S-1 filing relates to the issuance of up to 5,177,500 shares of common stock issuable upon exercise of warrants and the offer and sale of up to 90,069,340 shares of common stock by selling stockholders.

10-Q filing | 10.4M shares outstanding

10-Q filing | 10.4M shares outstanding

8-K filing: Alpha Healthcare Acquisition Corp. entered into a business combination agreement with Humacyte, Inc., involving the acquisition of Humacyte in exchange for Alpha Healthcare's Class A common stock and potential additional shares based on stock performance after the closing of the Business Combination. ($175.0M proceeds)

10-K filing | 10.4M shares outstanding

10-Q filing | 10.4M shares outstanding

8-K filing: Alpha Healthcare Acquisition Corp. completed its initial public offering of 10,000,000 units at $10.00 per unit, generating gross proceeds of $100,000,000, and simultaneously completed the private sale of 355,000 units to the Sponsor, Oppenheimer and Northland at $10.00 per unit, generating gross proceeds of $3,550,000. ($103.55M proceeds)

S-1/A filing: Initial public offering of units, each consisting of one share of Class A common stock and one-half of one redeemable warrant, to effect a business combination in the healthcare industry.

S-1/A filing: Initial public offering of 10,000,000 units at $10.00 per unit, each unit consisting of one share of Class A common stock and one-half of one redeemable warrant.

S-1 filing: Initial public offering of units, each consisting of one share of Class A common stock and one-half of one redeemable warrant, to raise funds for a business combination in the healthcare industry.